MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.

about

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.

Item

http://www.wikidata.org/entity/Q55361006

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

MRI-based response patterns du ...... n patients with breast cancer.

@en

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological

@nl

type

Item

label

MRI-based response patterns du ...... n patients with breast cancer.

@en

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological

@nl

prefLabel

MRI-based response patterns du ...... n patients with breast cancer.

@en

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological

@nl

P1476

MRI-based response patterns du ...... in patients with breast cancer

@en

P2093

Evert-Jan G Boerma

http://www.w3.org/2001/XMLSchema#string

Janneke B Houwers

http://www.w3.org/2001/XMLSchema#string

Kelly M A Dreuning

http://www.w3.org/2001/XMLSchema#string

Loes F S Kooreman

http://www.w3.org/2001/XMLSchema#string

Marc B I Lobbes

http://www.w3.org/2001/XMLSchema#string

Marjolein L Smidt

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review

Overview of resistance to systemic therapy in patients with breast cancer.

Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.

Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer

Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.

Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy.

P2888

s13058-018-0950-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13058-018-0950-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ritse Mann

Briete Goorts

P577

2018-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103453759

http://www.w3.org/2001/XMLSchema#string

P698

29669584

http://www.w3.org/2001/XMLSchema#string

P932

5907188

http://www.w3.org/2001/XMLSchema#string